Primary aldosteronism: diagnostic and therapeutic considerations

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Hypertension Research

Background:

• Primary aldosteronism (PA) is increasingly recognized as a prevalent condition in hypertensive patients.
• Prevalence estimates range from 5-10% in mild to moderate hypertension to approximately 20% in resistant hypertension.
• This represents a significant increase compared to historical data suggesting PA was a rare condition (<1%).

Purpose of the Study:

• To highlight the rising prevalence of primary aldosteronism (PA) as a cause of hypertension.
• To emphasize the importance of accurate PA diagnosis for effective patient management.
• To discuss current screening and confirmatory diagnostic approaches for PA.

Main Methods:

• Review of recent evaluations and epidemiological data on primary aldosteronism prevalence.
• Discussion of diagnostic strategies, including screening with the plasma aldosterone to plasma renin activity ratio.
• Emphasis on confirmatory testing for autonomous aldosterone secretion.

Main Results:

• Primary aldosteronism is now the most common secondary cause of hypertension.
• PA prevalence is significantly higher than previously estimated, particularly in resistant hypertension.
• The aldosterone-to-renin ratio serves as an effective screening tool with high negative predictive value.

Conclusions:

• Accurate identification of primary aldosteronism is essential for appropriate therapeutic interventions.
• Specific therapies include aldosterone antagonists or surgical removal of aldosterone-producing adenomas.
• Further research is needed to understand the reasons behind the increased prevalence of PA.